MALT1 and cholangiocarcinoma: Accordingly, regorafenib treatment of CCA cells not only decreases MALT1 levels, but also reduces the expression of NF-κB target genes, such as IL1B and CXCL8, which correlate with CCA cell growth and survival [92].